Tumor Biology

, Volume 36, Issue 3, pp 1803–1810 | Cite as

Evaluation of NIN/RPN12 binding protein inhibits proliferation and growth in human renal cancer cells

  • Jian-wei Jia
  • Ai-qin Liu
  • Yun Wang
  • Fen Zhao
  • Li-ling Jiao
  • Jun Tan
Research Article


The targeted delivery of small interfering RNA (siRNA) to specific tumor tissues and tumor cells remains as one of the key challenges in the development of RNA interference as a therapeutic application. The ribosome assembly factor NIN/RPN12 binding protein (NOB1) has been suggested to be essential for processing of the 20S pre-rRNA to the mature 18S rRNA, and is also reported to participate in proteasome biogenesis. However, it is unclear whether NOB1 is involved in tumor cells growth. The aim of this study was to determine whether the suppression of lentivirus mediated NOB1 siRNA inhibits the growth of human clean cell carcinoma (ccRCC) cells, further focused on NOB1 as a possible therapeutic target for renal cell carcinoma treatment. NOB1 deletion that caused significant decline in cell proliferation was observed in both 786-O and ACHN cell lines as investigated by MTT assay. Further, the number and size of the colonies formed were also significantly reduced in the absence of NOB1. Moreover, NOB1 gene knockdown arrested the cell cycle and inhibited cell cycle-related protein expression. The Kaplan-Meier survival curves revealed that low NOB1 expression was associated with poor prognosis in ccRCC patients. Collectively, these results indicate that NOB1 plays an essential role in renal cell cancer cell proliferation, and its gene expression could be a therapeutic target.


Renal cell carcinoma shRNA NOB1 Cellular proliferation 


Conflicts of interest



  1. 1.
    Miyamoto H, Miller JS, Fajardo DA, Lee TK, Netto GJ, Epstein JI. Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol Int. 2010;60:1–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Mulders PF, Brouwers AH, Hulsbergen-van der Kaa CA, van Lin EN, Osanto S and de Mulder PH. [Guideline’Renal cell carcinoma’]. Ned Tijdschr Geneeskd 2008; 152: 376–380.Google Scholar
  3. 3.
    Zhang G, Zhang Z, Liu Z. Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells. Tumour Biol. 2013;34:1887–94.CrossRefPubMedGoogle Scholar
  4. 4.
    Parker AS, Eckel-Passow JE, Serie D, Hilton T, Parasramka M, Joseph RW, Wu KJ, Cheville JC and Leibovich BC. Higher Expression of Topoisomerase II Alpha Is an Independent Marker of Increased Risk of Cancer-specific Death in Patients with Clear Cell Renal Cell Carcinoma. Eur Urol 2013;Google Scholar
  5. 5.
    Mulders PF. Renal cell carcinoma. World J Urol. 2008;26:113.CrossRefPubMedGoogle Scholar
  6. 6.
    Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373:1119–32.CrossRefPubMedGoogle Scholar
  7. 7.
    Li W, Zhu W, Che J, Sun W, Liu M, Peng B, et al. Microarray profiling of human renal cell carcinoma: identification for potential biomarkers and critical pathways. Kidney Blood Press Res. 2013;37:506–13.CrossRefPubMedGoogle Scholar
  8. 8.
    Kluge R, Giesen K, Bahrenberg G, Plum L, Ortlepp JR, Joost HG. Quantitative trait loci for obesity and insulin resistance (Nob1, Nob2) and their interaction with the leptin receptor allele (LeprA720T/T1044I) in New Zealand obese mice. Diabetologia. 2000;43:1565–72.CrossRefPubMedGoogle Scholar
  9. 9.
    Veith T, Martin R, Wurm JP, Weis BL, Duchardt-Ferner E, Safferthal C, et al. Structural and functional analysis of the archaeal endonuclease Nob1. Nucleic Acids Res. 2012;40:3259–74.CrossRefPubMedGoogle Scholar
  10. 10.
    Tone Y, Toh EA. Nob1p is required for biogenesis of the 26S proteasome and degraded upon its maturation in Saccharomyces cerevisiae. Genes Dev. 2002;16:3142–57.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Fatica A, Oeffinger M, Dlakic M, Tollervey D. Nob1p is required for cleavage of the 3′ end of 18S rRNA. Mol Cell Biol. 2003;23:1798–807.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Oehler VG, Yeung KY, Choi YE, Bumgarner RE, Raftery AE, Radich JP. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood. 2009;114:3292–8.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Li W, Liu M, Feng Y, Xu YF, Huang YF, Che JP, Wang GC, Yao XD and Zheng JH. Downregulated miR-646 in clear cell renal carcinoma correlated with tumour metastasis by targeting the nin one binding protein (NOB1). Br J Cancer 2014;Google Scholar
  14. 14.
    Deschamps C. Retraction. Up-regulation of NOB1 in esophageal squamous cell carcinoma (p). Dis Esophagus 2008; 21: 574.Google Scholar
  15. 15.
    Li XY, Luo QF, Li J, Wei CK, Kong XJ, Zhang JF, et al. Clinical significance of NOB1 expression in breast infiltrating ductal carcinoma. Int J Clin Exp Pathol. 2013;6:2137–44.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Che JP, Li W, Yan Y, Liu M, Wang GC, Li QY, et al. Expression and clinical significance of the nin one binding protein and p38 MAPK in prostate carcinoma. Int J Clin Exp Pathol. 2013;6:2300–11.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, et al. and Nccn. Non-small cell lung cancer. J Natl Compr Cancer Netw. 2012;10:1236–71.Google Scholar
  18. 18.
    Liu K, Gu MM, Chen HL and You QS. NOB1 in Non-small-cell Lung Cancer: Expression Profile and Clinical Significance. Pathol Oncol Res 2013;Google Scholar
  19. 19.
    Pertschy B, Schneider C, Gnadig M, Schafer T, Tollervey D, Hurt E. RNA helicase Prp43 and its co-factor Pfa1 promote 20 to 18S rRNA processing catalyzed by the endonuclease Nob1. J Biol Chem. 2009;284:35079–91.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kim SP, Crispen PL, Thompson RH, Weight CJ, Boorjian SA, Costello BA, et al. Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma. Cancer. 2012;118:4412–20.CrossRefPubMedGoogle Scholar
  21. 21.
    Rosa R, Damiano V, Nappi L, Formisano L, Massari F, Scarpa A, et al. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer. Br J Cancer. 2013;109:686–93.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Li Y, Ma C, Qian M, Wen Z, Jing H, Qian D. Downregulation of NOB1 suppresses the proliferation and tumor growth of non-small cell lung cancer in vitro and in vivo. Oncol Rep. 2014;31:1271–6.PubMedGoogle Scholar
  23. 23.
    Han Y, Hong L, Qiu J, Qiao L, Zhong C, Xue T, et al. Preparation and characterization of a novel monoclonal antibody specific to human NOB1 protein. Hybridoma (Larchmt). 2008;27:187–90.CrossRefGoogle Scholar
  24. 24.
    Zhang Y, Ni J, Zhou G, Yuan J, Ren W, Shan Y, et al. Cloning, expression and characterization of the human NOB1 gene. Mol Biol Rep. 2005;32:185–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Lamanna AC, Karbstein K. Nob1 binds the single-stranded cleavage site D at the 3′-end of 18S rRNA with its PIN domain. Proc Natl Acad Sci U S A. 2009;106:14259–64.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Li W, Liu M, Xu YF, Feng Y, Che JP, Wang GC, et al. Combination of quercetin and hyperoside has anticancer effects on renal cancer cells through inhibition of oncogenic microRNA-27a. Oncol Rep. 2014;31:117–24.PubMedGoogle Scholar
  27. 27.
    Mahon TM, Brennan P, O’Neill LA. Evidence for a redox-sensitive protein tyrosine kinase in nuclear factor kappa B activation and interleukin 2 production in EL4.NOB1 cells. Biochem Soc Trans. 1993;21:389S.CrossRefPubMedGoogle Scholar
  28. 28.
    Garimella SV, Gehlhaus K, Dine JL, Pitt JJ, Grandin M, Chakka S, et al. Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening. Breast Cancer Res. 2014;16:R41.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Unger GM, Kren BT, Korman VL, Kimbrough TG, Vogel RI, Ondrey FG, et al. Mechanism and efficacy of Sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma. Mol Cancer Ther. 2014;13:2018–29.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Lin Y, Peng S, Yu H, Teng H, Cui M. RNAi-mediated downregulation of NOB1 suppresses the growth and colony-formation ability of human ovarian cancer cells. Med Oncol. 2012;29:311–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G, Cleton-Jansen AM. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol. 2010;220:24–33.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Jian-wei Jia
    • 1
  • Ai-qin Liu
    • 2
  • Yun Wang
    • 3
  • Fen Zhao
    • 3
  • Li-ling Jiao
    • 4
  • Jun Tan
    • 5
  1. 1.Department of OncologyThe Third Affiliated Hospital of Xinxiang Medical UniversityXinxiangChina
  2. 2.Department of OphthalmologyThe Third Affiliated Hospital of Xinxiang Medical UniversityXinxiangChina
  3. 3.Department of PediatricsThe First Affiliated Hospital of Xinxiang Medical UniversityWeihuiChina
  4. 4.Department of SupplyThe First Affiliated Hospital of Xinxiang Medical UniversityWeihuiChina
  5. 5.Department of NeurologyThe Third Affiliated Hospital of Xinxiang Medical UniversityXinxiangChina

Personalised recommendations